On September 30, 2003, Boston University and the University of Texas at Galveston were each awarded $120 million by the National Institute of Allergy and Infectious Diseases to build a biosafety level 4 laboratory. Nine regional biocontainment laboratories were funded along with these two national biocontainment laboratories. In announcing the awards, Secretary of Health and Human Services Tommy Thompson described them as “a major step towards being able to provide Americans with effective therapies, vaccines and diagnostics for diseases caused by agents of bioterror as well as for naturally occurring emerging infections.”1